1. Market Research
  2. > Pharmaceutical Market Trends
  3. > IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Greece

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Table Of Contents

IMS Pharmaceutical Pricing and Reimbursement Concise Guide: Greece
GREECE 1
HEALTHCARE SYSTEM1
Facts and Figures 1
Market Indicators2
Provision and Funding 4
Background4
National Health Network5
Uninsured 5
Healthcare Expenditure 6
Pharmaceutical Expenditure7
Government Debt Owed to Industry 7
PRICING7
Prescription Drugs7
Application 8
Procedure 8
Appeals9
EOPYY Price Negotiation Committee 9
Discounts and Rebates 10
Drug Price Bulletin11
Off-patent Originals and Generics 12
Generic Drugs 12
Generics with No Off-patent Comparator13
Dynamic Pricing13
Hospital Drugs14
Pricing Regulations14
E-Tenders 14
OTC Drugs 15
REIMBURSEMENT 15
Admission to Reimbursement 15
Positive List15
Negative List17
Reimbursement Categories 17
Reimbursement Prices18
Therapeutic Reference Pricing 18
Active Ingredient-based Reference Pricing 19
Hospital Reimbursement19
Formularies19
Funding20
High-cost Hospital Drugs20
Changes in Reimbursement Status 20
Delisting from Reimbursement 20
Removal of Reference Pricing Exemption21
Changes in Reimbursement Prices 21
Price Reviews 21
Greece, Pharmaceutical Pricing and Reimbursement Concise Guide
v
Off-patent Branded Originals21
Dynamic Pricing for Generics 22
Ad-hoc Price Cuts22
PHARMACOECONOMICS23
Pharmacoeconomic Requirements23
PRICE BUILD UP 23
Wholesalers 23
Margins 23
Discounts 24
Background25
Retail Pharmacies 25
Margins 25
Rebates 27
Discounts 28
Background29
Dispensing Doctors 30
Sales Tax 30
COST CONTAINMENT 31
Industry Paybacks31
Clawback 31
Direct Distribution 33
Quarterly Rebates 33
Other Rebates 33
Electronic Reporting System for Rebates 33
Overdue Rebate Payments 34
Promotional Costs34
Promotional Expenditure 34
Payments to Healthcare Professionals 35
SFEE Code of Ethics35
Patient Co-payments36
Out-patient Drugs 36
In-patient Drugs 37
Non-reimbursed Drugs 37
Healthcare 37
Prescribing Controls38
Prescribing Limits 38
Generic Prescribing 38
Prior Authorisation 40
E-prescribing40
Therapeutic Guidelines40
Prescribing Restrictions41
Off-label Prescribing 41
Time Limits 42
Generics42
Rx-to-OTC Switches 43
Procedure 43
Liberalisation of OTC Sales43
Greece, Pharmaceutical Pricing and Reimbursement Concise Guide
vi
OTC Market 43
Parallel Trade44
FUTURE DEVELOPMENTS 44
Outlook44
Macroeconomic Situation 44
Pharmaceutical Policy 45
OTC Price Liberalisation45
DRG Reform45
Income Related Co-payments 46
Health Technology Assessment46
E-Health46
NAMES and ADDRESSES 47

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025 Summary Sales of dyslipidemia therapeutics is estimated to be approximately $11.2B across the 7MM in 2015, encompassing the ...

PharmaFocus: Tauopathies - Global Market Analysis

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.